3D Printing Drug Market - Demand for Instantaneous Soluble Drugs That Can Disperse Easily In the Mouth Is the Major Factor That Drives the Growth of the Global Market

The 3D Printing Drug Market is estimated at $ 278 million in 2020 and is expected to grow at a CAGR of 6.5% from 2020 to 2030, to $ 522 million by 2030. The US market holds the largest market share in 2020.

3D printed drugs are drugs made with 3D printing technology used to treat patients suffering from swallowing disorders. 3D printed drugs have a porous structure that can be rapidly degraded inside the mouth. Aprecia Pharmaceuticals Companys SPRITAM levetiracetam is the first 3D printing agent approved by the US Food and Drug Administration (FDA) in August 2015.

Continuing technology development in 3D printing technology in developing countries, increased epidemic outbreaks and increased awareness of 3D printing technology are driving market growth. However, market growth is expected to be limited due to the absence of government regulations related to these drugs and the adverse effects of 3D printing medicines.

The global 3D printing drug market is analyzed based on forecasting scenarios such as low-growth scenarios, medium-severity scenarios and rapid growth scenarios.

Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/4508

The key players profiled in this report include
• Aprecia Pharmaceuticals
• GlaxoSmithKline Plc.
• Hewlett Packard Caribe
• BV LLC
• 3D Printer Drug Machine
• FabRx Ltd.

The organizations engaged in the research of 3D printed drugs included in this report are UCL School of Pharmacy, University of Glasgow, University College London, The University of Nottingham, and National University of Singapore.

According to low growth scenario, the U.S. is anticipated to account for the highest market share in 2020, and rest of North America market is expected to grow at the highest rate, registering the CAGR of 5.1% by 2030.

Make an Enquiry before Buy @ https://www.alliedmarketresearch.com/purchase-enquiry/4508

Europe is estimated to account for four-sevenths share in 2020, and is expected to dominate the market throughout the forecast period, due to presence of well-established healthcare systems and increase in prevalence of dysphagia. In addition, increase in adoption of 3D printed drugs is anticipated to provide new growth opportunities for the key players in the European market.

However, Asia-Pacific is projected to grow at the highest growth rate during the analysis period, owing to increase in healthcare expenditure, rise in awareness related to 3D printing technique, presence of large patient pool, and developments in healthcare infrastructure.

Key Findings of 3D Printed Drugs Market:
• In North America, the U.S. is anticipated to dominate the market in 2020, whereas rest of North America is projected to grow at the highest CAGR during the forecast period.
• Germany was the major shareholder in the European 3D printed drugs market in 2016.
• Asia-Pacific is expected to register the highest growth rate in future.
• Australia is expected to grow at the highest CAGR in the Asia-Pacific 3D printed drugs market.

Access Full Summery @ https://www.alliedmarketresearch.com/3d-printed-drugs-market

About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Contact:

David Correa

5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States

Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975

help@alliedmarketresearch.com

This release was published on openPR.